BASEL, Switzerland,
Aug. 28, 2018 /PRNewswire/
-- Myovant Sciences (NYSE: MYOV), a leading
clinical-stage biopharmaceutical company focused on women's health
and endocrine diseases, today announced its participation in the
following upcoming investor conferences:
- Baird 2018 Global Healthcare Conference in New York. Lynn
Seely, M.D., Myovant's President and Chief Executive
Officer, will present on Wednesday,
September 5, 2018, in a session scheduled to begin at
4:20 p.m. ET. The presentation will
be featured in a live webcast and can be accessed via the Events
page under the Investors and Media section of Myovant's website at
www.myovant.com. Please connect to the company's website at least
15 minutes prior to the presentation to ensure adequate time for
any software download that may be required to listen to the
webcast. A replay will also be available at the same location for
30 days following the conference.
- Citi's 13th Annual Biotech Conference in
Boston. Myovant will host meetings
with investors at the conference on Thursday, September 6, 2018.
About Myovant Sciences
Myovant Sciences is a
clinical-stage biopharmaceutical company focused on developing and
commercializing innovative therapies for the treatment of women's
health and endocrine diseases. Myovant's goal is to be the leading
global biopharmaceutical company focused on treating women's health
and endocrine diseases in areas of high unmet medical need.
Myovant's lead product candidate is relugolix, an oral, once-daily,
small molecule that acts as a GnRH receptor antagonist. Myovant has
initiated three clinical programs for relugolix consisting of five
international Phase 3 clinical trials, two in women with heavy
menstrual bleeding associated with uterine fibroids (LIBERTY 1 and
2), two in women with endometriosis-associated pain (SPIRIT 1 and
2), and one in men with advanced prostate cancer (HERO). Myovant is
also developing MVT-602, a kisspeptin agonist, for the treatment of
female infertility as part of assisted reproduction. Takeda
Pharmaceuticals International AG has granted Myovant an exclusive,
worldwide license to develop and commercialize relugolix (excluding
Japan and certain other Asian
countries where Takeda retains exclusive rights) and an exclusive
license to develop and commercialize MVT-602 in all countries
worldwide. Over time, Myovant intends to expand its development
pipeline to include other potential treatments for women's health
and endocrine diseases. For more information, please visit the
company's website at www.myovant.com.
Investor Contact:
Frank
Karbe
Chief Financial Officer
Myovant Sciences, Inc.
investors@myovant.com
Media Contact:
Julie
Normart
W2O pure
jnormart@purecommunications.com
415.946.1087
View original content with
multimedia:http://www.prnewswire.com/news-releases/myovant-sciences-to-participate-in-two-upcoming-investor-conferences-300702897.html
SOURCE Myovant Sciences